Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta‐analysis

@article{Niemeijer2014ChemotherapyWC,
  title={Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta‐analysis},
  author={N. D. Niemeijer and G. Alblas and L. T. Hulsteijn and O. Dekkers and Epm Corssmit},
  journal={Clinical Endocrinology},
  year={2014},
  volume={81}
}
  • N.D. Niemeijer, G. Alblas, +2 authors Epm Corssmit
  • Published 2014
  • Medicine
  • Clinical Endocrinology
  • Chemotherapy with cyclophosphamide, vincristine and dacarbazine (CVD) can be used for palliative treatment of malignant pheochromocytoma and paraganglioma. However, the precise effect of this chemotherapeutic regimen on tumour volume is unclear. The main objective of this study was to perform a systematic review and meta‐analysis assessing the effect of chemotherapy with CVD on tumour volume in patients with malignant paraganglioma/pheochromocytoma. 
    76 Citations
    Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment.
    • L. Fishbein
    • Medicine
    • Hematology/oncology clinics of North America
    • 2016
    • 63
    • Highly Influenced

    References

    SHOWING 1-10 OF 37 REFERENCES
    Clinical review: Current treatment of malignant pheochromocytoma.
    • 162
    • PDF
    Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
    • 135
    Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    • 134
    • PDF
    Diagnostic management of benign and malignant pheochromocytoma.
    • 41
    Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    • F. Forrer, I. Riedweg, H. Mäcke, J. Mueller-Brand
    • Medicine
    • The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
    • 2008
    • 94